INCATE (the INCubator for Antibacterial Therapies in Europe) and BIOASTER, the French Microbiology Technology Research Institute, have announced this week the beginning of a new partnership that aims to improve the support to innovators to fight drug-resistant infections.
Antimicrobial resistance (AMR) is the ability of pathogens to prevent antibiotics from working against them and it was recently estimated by the Lancet to be attributable for 1.27million deaths in 2019 alone. This acute threat needs new antibiotics but the pipeline of antibiotic therapies is weak. There is an urgent need to expand the pipeline of new antimicrobial therapies.
Read the complete Press Release: HERE.